Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 19Carcinoma, Hepatocellular 18Stomach Neoplasms 17Nasopharyngeal Carcinoma 15Triple Negative Breast Neoplasms 13Esophageal Squamous Cell Carcinoma 13Breast Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Esophageal Neoplasms 11Uterine Cervical Neoplasms 10Colorectal Neoplasms 10Sarcoma 9Melanoma 6Recurrence 5Neoplasm Metastasis 5Lung Neoplasms 5Hodgkin Disease 5Cholangiocarcinoma 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Osteosarcoma 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Liver Neoplasms 3Glioblastoma 3Gestational Trophoblastic Disease 3Endometrial Neoplasms 3Biliary Tract Neoplasms 3Solid Tumor 2Rectal Neoplasms 2NSCLC 2

Interventions

pembrolizumab 32Gemcitabine 26Nivolumab 20atezolizumab 16Cisplatin 15avelumab 14Carboplatin 12Docetaxel 10enfortumab vedotin 9Magnetic Resonance Spectroscopy 8durvalumab 7Specimen Handling 7Paclitaxel 7Ipilimumab 6toripalimab 5pemigatinib 5cabozantinib 5vinflunine 4sacituzumab govitecan 4Taxes 4Pemetrexed 4Injections 4tislelizumab 3cabazitaxel 3Standard of Care 3Mitomycin 3Everolimus 3Albumin-Bound Paclitaxel 3zanidatamab 2sapanisertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Transitional Cell × camrelizumab × Clear all
NCT03827837 2022-07-01

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
265 enrolled
GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡